Drug Trial Radar · NCT00403767
An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: Apr 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
14,269
Actual
Start
Dec 2006
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- Collaborators
- Bayer
- First posted
- Nov 27, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of rivaroxaban with warfarin for the prevention of blood clots in the brain (referred to as stroke) and blood clots in other parts of the body referred to as non-central nervous system systemic embolism) in patients with non-valvular atrial fibrillation (a heart rhythm disorder).
Conditions
- Atrial Fibrillation
- Stroke
- Embolism
Interventions
RivaroxabanDrug
Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
WarfarinDrug
Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
Matching placebo for Rivaroxaban arm (Warfarin placebo)Drug
Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
Matching placebo for Warfarin arm (Rivaroxaban placebo)Drug
Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
Primary outcomes
What the sponsor says the trial is designed to measure.
- The Composite Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Non-Inferiority)Time frame: Up to 4 years
- The Composite of Event of Stroke/Non-CNS Systemic Embolism: Primary Efficacy (Superiority)Time frame: Up to 4 years
- The Composite Event of Major/Non-major Clinically Relevant Bleeding Events: Primary SafetyTime frame: Up to 4 years
Locations
932 sites in 44 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Dothan, Alabama
Site not named
Geneva, Alabama
Site not named
Mobile, Alabama
Site not named
Pell City, Alabama
Site not named
Glendale, Arizona
Site not named
Phoenix, Arizona
Site not named
Scottsdale, Arizona
Site not named
Tucson, Arizona
Site not named
Fort Smith, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Anaheim, California
Site not named
Bakersfield, California
Site not named
Carmichael, California
Site not named
Corona, California
Site not named
Fair Oaks, California
Site not named
Glendale, California
Site not named
Healdsburg, California
Site not named
Laguna Hills, California
Site not named
Long Beach, California
Site not named
Los Angeles, California
Site not named
Los Gatos, California
Site not named
Mission Viejo, California
Site not named
Modesto, California
Site not named
Mountain View, California
Site not named
Northridge, California
Site not named
Oakland, California
Site not named
Orange, California
Site not named
Pismo Beach, California
Site not named
Sacramento, California
Site not named
San Diego, California
Site not named
San Leandro, California
Site not named
Santa Clara, California
Site not named
Santa Monica, California
Site not named
Santa Rosa, California
Site not named
Sylmar, California
Site not named
Torrance, California
Site not named
Ventura, California
Site not named
Yuba City, California
Site not named
Boulder, Colorado
Showing 40 of 932 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.